Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/BridgeBio to report Q1 2026 financial results and updates on May 7, 2026

BBIO

$82.33

-$0.33 -0.41%

BridgeBio to report Q1 2026 financial results and updates on May 7, 2026

Company Fundamentals

30 Apr 2026

GlobeNewsWire

View Source

Neutral

BridgeBio Pharma, a biopharmaceutical company focused on genetic conditions, will release its first quarter 2026 financial results and business updates after market close on May 7, 2026. The company will hold a conference call at 4:30 pm ET the same day to discuss these results and program updates. Investors can access the live webcast via the BridgeBio website, with a replay available for 30 days. This update is important as it provides insights into BridgeBio's progress in developing medicines for underserved genetic conditions and its commercial outlook.

More News (BBIO)

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma remains a strong buy due to regulatory approvals for its drug acoramidis and positive clinical data for infigratinib in achondroplasia. The company expects $180.6 million in U.S. net product revenue by Q1 2026 and targets a $2.9 bill...

Analyst Insights

Bullish

3 days ago